Pilot study to ensure national availability to new antibiotics of of special medical value
| Reference number | |
| Coordinator | Folkhälsomyndigheten |
| Funding from Vinnova | SEK 22 000 000 |
| Project duration | January 2019 - June 2023 |
| Status | Completed |
| Venture | 2017-01599-en |
Important results from the project
To conduct a pilot study for a new reimbursement model to ensure availability of certain antibiotics, as well as to evaluate the model´s efficiency and effectiveness. A balanced assessment of the model should be made and lead to a recommendation whether the reimbursement model that was piloted should be extended in Sweden. The pilot study shows that the reimbursement model is appropriate and effective to ensure the availability of identified antibiotics. Through it, Sweden gained access to several new medicines and also earlier than other comparable European countries.
Expected long term effects
Through the pilot study, the Public Health Agency of Sweden (PHAS) signed agreements with four pharmaceutical companies for five particularly medically important antibiotic products. In summary, the PHAS believes that a model with partially de-linked compensation, similar to the one tested in the pilot study, can strengthen the availability of particularly medically important antibiotics in an effective and efficient manner. The PHAS should be tasked with procuring availability with associated funding, while the regions continue to pay for their actual drug use.
Approach and implementation
The pilot study is based on the Public Health Agency of Sweden´s report in a previous government assignment (dnr S2015/05372/FS) and has been carried out in accordance with existing laws and regulations. The project was divided into a preparation phase (the principles for the model and organization was determined and a legal investigation was carried out), an implementation phase (procurement, contract signing and management of agreements) and an evaluation phase. The final report of the assignment is in two parts, of which part 1 was published in January and part 2 in may 2023.